Table 1. Clinical Inputs for the Response-Based PSM Model.
| Model Input | Parameter Value | Source | Model Application |
|---|---|---|---|
| MRD-negative patients, % (95% CI)a | |||
| DBTd | 63.7 (59.5- 67.8)b | CASSIOPEIA (ITT population) |
To determine proportion of patients achieving MRD negativity |
| BTd | 43.5 (39.3-47.8)b | CASSIOPEIA (ITT population) |
|
| HR applied to OS parametric extrapolation, HR (95% CI) | |||
| MRD- vs MRD+ | 0.60 (0.50-0.72)c | Analysis conducted on Munshi et al20 | To estimate survival outcomes for MRD- BTd patients (applied to BTd MRD+) |
| DBTd MRD+ vs BTd MRD+ | 0.73 (0.40-1.35) | CASSIOPEIA (landmark analysis) |
To estimate survival outcomes for MRD+ DBTd patients (applied to BTd MRD+) |
| DBTd MRD- vs BTd MRD- | 0.41 (0.16-1.04) | CASSIOPEIA (landmark analysis) |
To estimate survival outcomes for MRD- DBTd patients (applied to BTd MRD-) |
HR, hazard ratio; ITT, intention to treat; MRD+/-, minimal residual disease positive/negative; OS, overall survival.
aThe proportion of patients achieving postconsolidation MRD negativity in the model was based on that in CASSIOPEIA, with a sensitivity threshold of 10-5 for MRD.
bDBTd vs BTd: P < .0001.
cThe HR used in the model differs slightly from the HR reported in Munshi et al20 due to the exclusion of the DBTd arm of the CASSIOPEIA trial and studies measuring MRD at 100-days post–autologous stem cell transplant from the analysis.